Germany and Israel
Coramaze Technologies focuses on developing new technologies to address unmet needs in the treatment of heart valve disease. The company’s Mitramaze® valve repair system is designed for the treatment of severe functional mitral regurgitation (fMR) through transfemoral implantation into a beating heart. Until recently, many patients with severe fMR were excluded from standard surgical mitral valve treatment options due to their advanced age or comorbidities.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.